Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01822-7
Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes. In this...
Conclusion: Overall, both in vitro and in vivo studies agree in one thing: SGLT-2 inhibitors are able to protect our heart independent of their glucose lowering effects. However, more research is ahead of us before we are able to comprehensively decipher their direct and indirect cellular targets and corresponding mechanism of action, in...
Share
Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37070931/
There were few clinical studies on the relationship between sodium glucose cotransporter 2 inhibitors (SGLT2i) and hematopoiesis in patients with diabetes (DM) and heart failure (HF) with consideration of systemic...
Conclusion: cCnagliflozin was associated with an increased hematocrit and hemoglobin in patients with diabetes and HF regardless of their volume status and characteristics.
Share
Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37095712/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: This study identified high residual risk for all-cause mortality and hospital readmission in real-world HF patients with LVEF < 50% despite GDMT. T2D and CKD aggravated the risk for these endpoints, indicating the intertwinement of HF with CKD and T2D. SGLT2i treatment that clinically benefits these different disease...
Share
The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37062643/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Our study showed that SGLT2is, particularly empagliflozin, significantly reverse cardiac remodeling in patients with heart failure. Empagliflozin may be a potentially promising agent to reverse cardiac remodeling in clinical practice.
Share
Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure - Current Treatment Options in Cardiovascular Medicine
Source : https://link.springer.com/article/10.1007/s11936-023-00979-4
Purpose of review To examine the emerging data for novel strategies being studied to improve use and dose titration of guideline-directed medical therapy (GDMT) for patients with heart failure (HF)....
Relevance: A large therapeutic gap between guideline-directed recommendations and real-world practice exists in the contemporary management of patients with HFrEF. Many strategies are being developed in an attempt to close this gap, as outlined in this review.
Share